Treatment of overactive bladder: what is on the horizon?

@article{Murphy2012TreatmentOO,
  title={Treatment of overactive bladder: what is on the horizon?},
  author={Alana M. Murphy and Ryan M. Krlin and Howard B. Goldman},
  journal={International Urogynecology Journal},
  year={2012},
  volume={24},
  pages={5-13}
}
There is still a need to develop additional effective and well-tolerated therapies for the treatment of overactive bladder (OAB). The purpose of this review is to discuss alternative therapies for idiopathic OAB that employ a unique mechanism of action or offer a novel application of an existing therapy. We performed a comprehensive literature review to identify alternative therapies and potential future treatments for idiopathic OAB. The use of botulinumtoxin for idiopathic OAB is on the rise… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
5 Citations
53 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Prospective, randomized clinical trial of a novel, noninvasive, patientmanaged neuromodulation system (PMNS) using a sacral patch for the treatment of patients with overactive bladder

  • AB Monga, R Dmochowski, D Miller, D Altman
  • Int Urogynecol J
  • 2011
Highly Influential
6 Excerpts

Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study

  • P Denys, L Le Normand, I Ghout
  • Eur Urol
  • 2012
Highly Influential
5 Excerpts

Randomized, double-blind, active-controlled phase III study to assess the longterm safety and efficacy of mirabegron in overactive bladder (OAB)

  • CR Chapple, S Kaplan, HD Mitcheson
  • Eur Urol
  • 2011
Highly Influential
6 Excerpts

The efficacy and safety of mirabegron with overactive bladder syndrome—results from a North American phase III trial

  • V Nitti, S Herschorn, S Auerbach, M Ayers, M Lee, N Martin
  • Eur Urol
  • 2011
Highly Influential
6 Excerpts

The efficacy and tolerability of mirabegron in patients with overactive bladder – results from a European-Australian phase III trial

  • V Khullar, J Cambronero, P Stroberg
  • Eur Urol
  • 2011
Highly Influential
6 Excerpts

Mahashabde A (2000) Absorption of oxybutynin from vaginal inserts: drug

  • A Schroder, RM Levin, BA Kogan, AK Das, F Kay
  • Int Urogynecol J
  • 2013
1 Excerpt

Recommends Approval of Mirabegron— Investigational Overactive Bladder Treatment from Astellas

  • FDA Advisory Committe
  • PR Newswire. 5 April 2012. Accessed 30 April
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…